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HIGHLY LIPOPHILIC CAMPTOTHECIN
INTERMEDIATES AND PRODRUGS AND
METHODS OF PREPARATION THEREOF

nicks are converted to irreversible and lethal double strand

DNA breaks during replication.

This application claims the bene?t of Us. Provisional
Patent Application Ser. No. 60/469,805 ?led on May 12,

5

2003.
This invention Was made With Government support under
NIH Grant Number lR0lCA63653. The Government may

The camptothecin class of anticancer agents have exhib
ited unusual reactivity in vivo, both With respect to drug
hydrolysis and blood protein interactions. These factors
have hindered the pharmaceutical development and clinical
implementation of camptothecins. In terms of hydrolysis,
each of the camptothecins shoWn in Table 1 contains an

ot-hydroxy-o-lactone pharmacophore.

have certain rights in this invention.

TABLE 1
Clinical candidates and FDA-approved analogs in the camptothecin family of antiturnor agents

Aqueous
Solubility

Compound

R10

Soluble

Topotecan/TPT

"

CDK602

Irinotecan/CPT- ll

R1

R2

R3

H

CH2NH(CH3)2

OH

H

H

C2H5NHCH(CH3)2

H

H

C2H5

H

GI-l472llC/GG-2ll

O

H
— CH2 — N

H

O

\

N — CH3

0/
Insoluble

Camptothecin

H

H

H

"

9-AC

H

NH2

H

H
H

9-NC/Rubitecan
SN-3 8
DB-67

H
C2H5
Si(CH3)2C(CH3)3

N02
H
H

H
OH
OH

H
H
H

MDCPT

H

H

<O—
O—

At physiological pH of 7 and above this functionality is

TECHNICAL FIELD

reactive, readily converting to the biologically inactive “ring
The present invention relates to novel intermediates and

opened” carboxylate form. Thus, as a result of the labile

prodrugs of highly lipophilic 7-silylalkylcamptothecins (si
latecans).
BACKGROUND OF THE INVENTION

Camptothecin and related analogs (Table l) are emerging

60

parent drug.

as a prominent class of agents useful in the treatment of

cancer. The camptothecins display a unique mechanism of
action: stabiliZation of the covalent binding of the enZyme
topoisomerase I (topo I), an intranuclear enZyme that is
overexpressed in a variety of tumor lines, to DNA. This

drug/enZyme/DNA complex leads to reversible, single
strand nicks. According to the fork collision model, the DNA

ot-hydroxy-o-lactone pharmacophore, an equilibrium is
established betWeen tWo distinct drug species: 1) the bio
logically active lactone form Where the lactone ring remains
closed; and 2) a biologically-inactive carboxylate form
generated upon the hydrolysis of the lactone ring of the

This hydrolysis problem With camptothecin and many

analogs (e.g. 9-aminocamptothecin, 9-nitrocamptothecin) is
65

exacerbated in human blood. In human blood and tissues,
the camptothecin equilibrium of active lactone form vs.
inactive carboxylate form can be strongly modulated by the
presence of human serum albumin (HSA). The lactone form

US 7,064,206 B1
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of camptothecin binds to HSA With moderate af?nity yet the
carboxylate form of camptothecin binds much more tightly
than the carboxylate, displaying the l50-fold enhancement

INVENTION

Our previous rational synthetic efforts described above
yielded a series of silatecan agents. 7-t-Butyldimethylsilyl
l0-hydroxycamptothecin, Which We have termed DB-67, is
an example of a silatecan that displays improved biological

in its a?inity. Thus, the preferential binding of the carboxy
late form to HSA drives the equilibrium to the right in favor

of the carboxylate, resulting in the lactone ring hydrolyZing
more rapidly and completely (than When camptothecin is in

properties. In the current invention We describe novel inter

mediates and prodrugs of DB-67 and related 7-silylcamp

an aqueous solution Without HSA).

tothecins or silatecans.

The development of 7-silylcamptothecins (or silatecans)

The invention includes compounds With the folloWing

has resulted in the identi?cation of agents With improved
human blood stabilities and activities. Recent rational design
efforts have resulted in the identi?cation of A,B-ring modi

structures A and B:

?ed camptothecins displaying improved human blood sta
bilities combined With potent anti-topoisomerase I activities.
Dual 7,10-substitution (Where the l0-substituent is a

R1

hydroxy group) results in camptothecins displaying vastly
improved human blood stabilities. SN-38 contains this dual
7-alkyl-l0-hydroxy substitution pattern and in 1994 it Was
shoWn that these structural modi?cations block SN-38 from

20

associating With the high affinity camptothecin carboxylate
binding pocket on HSA.
More recently the design of another dual 7,10-modi?ed
camptothecin has been described. The neW agent is 7-t

butyldimethylsilyl-lO-hydroxycamptothecin

(DB-67).

25

DB-67 displays markedly improved human blood stability

R1

and potent anti-topoisomerase I anticancer activity. The
design of DB-67 Was based upon the folloWing tWo consid

erations: 1) dual 7,10-substitution patterns eliminate the
highly speci?c binding of carboxylate form over lactone
form by HSA; and 2) lactone stabiliZation is further pro

30

moted by enhanced lipophilicity or lipid bilayer partitioning.

Lipophilicity promotes camptothecin drug stability by
favoring lactone partitioning into blood cells, thereby pro
tecting the active lactone forms from hydrolysis. The key

35

ot-hydroxy-o-lactone pharmacophore in DB-67 displays
superior stability in human blood When compared With
FDA-approved topotecan, CPT-ll, and several other clini
cally relevant camptothecin analogs. DB-67 displayed a tl/2
of 130 min. and a % lactone at equilibrium value of 30 in

40

human blood; the t-butyldimethylsilyl group enhances lipo
philicity and thereby promotes drug associations With blood
cells. DB-67 is 25 times lipophilic than camptothecin and

acyloxy group, OC(O)ORl2 wherein R12 is an alkyl group,
a carbamoyloxy group, a halogen, a hydroxy group, a nitro

readily incorporates as its active lactone form into cellular

and liposomal bilayers. Equally important, the dual 7-alkyl

group, a cyano group, an aZido group, a formyl group, a
45

silyl and l0-hydroxy substitution in DB-67 blocks the
associations of the carboxylate form of DB-67 With the high

enhanced lipophilicity and altered HSA interactions provide

O(CH2)PO Wherein p represents an integer 1 through 6; R3
50

pared With clinically relevant camptothecins containing the
conventional ot-hydroxy-o-lactone pharmacophore.
In vitro cytotoxicity assays have shoWn that DB-67 is of

integer 1 through 6; R4 is H, F, an alkyl group, an alkenyl
group, an alkynyl group, a trialkylsilyl group or an alkoxy
55

reveal that DB-67 forms more stable topoisomerase I cleav
age complexes than camptothecin or SN-38. In terms of in

vitro potency, DB-67 has been shoWn to display activity
against human glioma in a murine model. Overall, these
stability and activity pro?les of DB-67 indicate hoW rational
drug design can result in neW, highly lipophilic agents

DETAILED DESCRIPTION OF THE

group; R5 is a Cl_l5 alkyl group, an allyl group, a benZyl
group or a propargyl group; R6, R7 and R8 are independently
a Cl_l5 alkyl group, a C2_l5 alkenyl group, a C2_l5 alkynyl
group, an aryl group or a (CH2) Rl5 group, Wherein q is an

integer between 1 and 15 and R1 is a hydroxy group, alkoxy
60

group, an amino group, an alkylamino group, a dialkylamino
group, a halogen atom, a cyano group or a nitro group; R9

is a hydrogen, an alkyl group, an alkenyl group, an alkynyl
group, an alkoxy group, an aryloxy group, or an acyloxy
group; R10 is an alkylene group, an alkenylene group or an

displaying improved pharmacological properties.
In this invention We describe novel, highly lipophilic
intermediates and prodrugs of DB-67 and other silatecans.

is H, a nitro group, a halogen atom, an amino group, a

hydroxy group, or a cyano group, or R2 and R3 together form
a group of the formula O(CH2)PO Wherein p represents an

comparable potency relative to camptothecin and l0-hy
droxycamptothecin, as Well as the FDA approved analogs
topotecan and CPT-ll. In addition, cell-free cleavage assays

hydraZino group, C(O)Rl3 wherein R13 is an alkyl group, an
alkoxy group, an amino group or a hydroxy group, SRM,
wherein R14 is hydrogen, C(O)Rl3 , an alkyl group, or an aryl
group; or R1 and R2 together form a group of the formula

af?nity carboxylate binding pocket on HSA. Together, the
DB-67 With the highest human blood stability When com

wherein R1 and R2 are independently the same or different
and are hydrogen, an alkyl group, an alkenyl group, an
alkynyl group, an alkoxy group, an aryloxy group, an

65

alkynylene group.
The invention also includes compounds With the folloW
ing structures C and D:

US 7,064,206 B1
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The formulas of such compounds as set forth herein cover

and/or include each such form.

The terms “alkyl”, “aryl” and other groups refer generally
to both unsubstituted and substituted groups unless speci?ed
to the contrary. Unless otherWise speci?ed, alkyl groups are
hydrocarbon groups and are preferably C liC 1 5 (that is,
having 1 to 15 carbon atoms) alkyl groups, and more
preferably CFC1O alkyl groups, and can be branched or
unbranched, acyclic or cyclic. The above de?nition of an
alkyl group and other de?nitions apply also When the group
is a substituent on another group (for example, an alkyl

OH

group as a substituent of an alkylamino group or a dialky

lamino group). The term “aryl” refers to phenyl or napthyl.
As used herein, the terms “halogen” or “halo” refer to ?uoro,
chloro, bromo and iodo.
The term “alkoxy” refers to 4ORd, Wherein Rd is an alkyl

R1

group. The term “aryloxy” refers to iORe, Wherein Re is an

aryl group. The term acyl refers to iC(O)Rf. The term
20

“alkenyl” refers to a straight or branched chain hydrocarbon
group With at least one double bond, preferably With 2*15
carbon atoms, and more preferably With 2*10 carbon atoms

(for example, 4CH=CHRg or iCH2CH=CHRg). The
OH

25

term “alkynyl” refers to a straight or branched chain hydro
carbon group With at least one triple bond, preferably With
2*15 carbon atoms, and more preferably With 2*10 carbon

atoms (for example, 4CECRh or ‘CH2 CECRh). The terms
“alkylene,” “alkenylene” and “alkynylene” refer to bivalent
wherein R1 and R2 are independently the same or different
and are hydrogen, an alkyl group, an alkenyl group, an
alkynyl group, an alkoxy group, an aryloxy group, an

forms of alkyl, alkenyl and alkynyl groups, respectively.
The groups set forth above, can be substituted With a Wide
30

variety of substituents to synthesiZe homocamptothecin ana

acyloxy group, OC(O)ORl2 wherein R12 is an alkyl group,

logs retaining activity. For example, alkyl groups may

a carbamoyloxy group, a halogen, a hydroxy group, a nitro

preferably be substituted With a group or groups including,
but not limited to, a benZyl group, a phenyl group, an alkoxy
group, a hydroxy group, an amino group (including, for

group, a cyano group, an aZido group, a formyl group, a

hydraZino group, C(O)Rl3 wherein R13 is an alkyl group, an
alkoxy group, an amino group or a hydroxy group, SRM,
wherein R14 is hydrogen, C(O)Rl3 , an alkyl group, or an aryl
group; or R1 and R2 together form a group of the formula

35

example, free amino groups, alkylamino, dialkylamino
groups and arylamino groups), an alkenyl group, an alkynyl
group and an acyloxy group. In the case of amino groups

O(CH2)PO Wherein p represents an integer 1 through 6; R3

(iNRaRb), R“ and Rh are preferably independently hydro

is H, a nitro group, a halogen atom, an amino group, a

gen, an acyl group, an alkyl group, or an aryl group. Acyl

hydroxy group, or a cyano group, or R2 and R3 together form
a group of the formula O(CH2)PO Wherein p represents an

40

integer 1 through 6; R4 is H, F, an alkyl group, an alkenyl

groups may preferably be substituted With (that is, Rf is) an
alkyl group, a haloalkyl group (for example, a per?uoroalkyl
group), an alkoxy group, an amino group and a hydroxy

group, an alkynyl group, a trialkylsilyl group or an alkoxy

group. Alkynyl groups and alkenyl groups may preferably

group; R5 is a Cl_l5 alkyl group, an allyl group, a benZyl
group or a propargyl group; R6, R7 and R8 are independently
a Cl_l5 alkyl group, a C2_l5 alkenyl group, a C2_l5 alkynyl

be substituted With (that is, Rg and Rh are preferably) a group
45

alkoxyalkyl group, an amino alkyl group and a benZyl

group, an aryl group or a (CH2) Rl5 group, Wherein q is an

group.
The term “acyloxy” as used herein refers to the group

integer betWeen 1 and 15 and R1 is a hydroxy group, alkoxy
group, an amino group, an alkylamino group, a dialkylamino
group, a halogen atom, a cyano group or a nitro group; R9
is a hydrogen, an alkyl group, an alkenyl group, an alkynyl
group, an alkoxy group, an aryloxy group, or an acyloxy
group; R10 is an alkylene group, an alkenylene group or an

alkynylene group; R11 is (CH2)LNRl6Rl7 Wherein L may be
an integer ranging from 1*30 and R16 and R17 are indepen

4OC(O)Rd.
50

The term “carbamoyloxy” as used herein refers to the

group wc(o)NR“Rb.
Amino and hydroxy groups may include protective
55

protecting groups as knoWn to those skilled in the art are
60

[3-hydroxylactone group can exist in racemic form, enantio

disclosed in Greene, T., Wuts, P. G. M., Protective Groups
in Organic Synthesis, Wiley (1991), the disclosure of Which
is incorporated herein by reference.
In general, R1, R2 and R3 are preferably not excessively
bulky to maintain activity of the resultant camptothecin

analog. Preferably, therefore, R1, R2 and R3 independently

alkyl group, an alkenyl group.

merically enriched from, and enantiomerically pure form.

groups as knoWn in the art. Preferred protective groups for

amino groups include tert-butyloxycarbonyl, formyl, acetyl,
benZyl, p-methoxybenZyloxycarbonyl, trityl. Other suitable

(CH) YCO2R18 Wherein Y may be an integer ranging from 1

All compounds of the present invention including the

The term “alkoxycarbonyloxy” as used herein refers to

the group 4OC(O)ORd.

dently the same or different and are hydrogen, a C1_l5 alkyl
group, a C2_l5 alkenyl group, a C2_ 15 alkynyl group, an aryl
group, a (CH2)YRl8 group, a (CH2)YC(O)Rl8 group or a
to 15 and R18 is a hydroxy group, a thiol group, an alkylthiol,
a silyl group, an alkoxy group, an amino group, an alky
lamino group, a dialkylamino group, a halogen atom, a
cyano group, a nitro group. R11 may also be a hydrogen, an

or groups including, but not limited to, an alkyl group, an

65

have a molecular Weight less than approximately 250. More

preferably R1, R2 and R3 independently have a molecular
Weight less than approximately 200.

US 7,064,206 B1
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pounds effective to display antileukemic and/or antitumor
(anticancer) behavior. Pharmaceutical compositions con

Some of the camptothecin analogs of the present inven
tion can be prepared for pharmaceutical use as salts With

inorganic acids such as, but not limited to, hydrochloride,

taining as an active ingredient of one of the compounds of

hydrobromide, sulfate, phosphate, and nitrate. The camp

the present invention including a pharmaceutically accept

tothecin analogs can also be prepared as salts With organic
acids such as, but not limited to, acetate, tartrate, fumarate,

able salt thereof in association With a pharmaceutically
acceptable carrier or diluent are also Within the scope of the

succinate, citrate, methanesulfonate, p-toluenesulfonate, and

present invention.
The novel compounds of the present invention display

stearate. Other acids can be used as intermediates in the

good biological activity While also possessing favorable
characteristics for active loading into liposomal particle drug

preparation of the compounds of the present invention and

their pharmaceutically acceptable salts.
such as, but not limited to, sodium hydroxide or calcium

delivery systems of the micelle type disclosed and described
in Us. Pat. Nos. 5,316,771; 5,552,156 and 5,736,156.
Pre-made liposomes can be ef?ciently loaded With the novel

hydroxide, to form opened E-ring analogs of compounds of

compounds of this invention using pH gradients.

the present invention. The intermediates thus obtained are
more soluble in Water and may be puri?ed to produce, after
treatment With an acid, a puri?ed form of the camptothecin

containing agent is loaded into the particle. For example, a
gradient created by ammonia gas diffusing out of the lipo

For puri?cation, administration or other purposes, the

E-ring (the lactone ring) may be opened With alkali metal

analogs of the present invention.
All the novel compounds of the present invention Whether
in racemic, enantiomerically enriched or enantiomerically
pure form display good biological activity While also pos
sessing favorable characteristics for active loading into

In brief, in the active core loading process an amine

20

lost NH3 from the interior of the liposome. Once inside the
acidic con?nes of the core, the compound/agent becomes
protonated and remains Within the core, as its positive

liposomal particle drug delivery systems of the micelle type
disclosed and described in Us. Pat. Nos. 5,316,771; 5,552,
156 and 5,736,156. Pre-made liposomes can be ef?ciently
loaded With any of the novel compounds of this invention

25

In brief, in the active core loading process an amine
30

some particle can result in diffusion or active loading of the

compound/agent of the present invention inWard to the core
of the particle. The chemical gradient across the membrane
creates a driving force for the compound/ agent to replace the
lost NH3 from the interior of the liposome. Once inside the
acidic con?nes of the core, the compound/agent becomes
protonated and remains Within the core, as its positive

liposomes can be actively and/or passively targeted to the
tumor, the liposome encapsulated compound/agent can be
effectively concentrated at the tumor site, therby reducing
exposure of the healthy host tissues to the cytotoxic agent
yet enhancing exposure at the tumor target.

The tumor targeted approach involving liposomal deliv
35
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achieved. Enhanced exposure at the tumor site in terms of
relative amounts of drug reaching the tumor can also be
achieved. Furthermore, enhanced exposure at the tumor site
can be achieved in terms of prolonging the exposure of drug
there.

The compounds of the present invention may be admin
istered in a dose Which is effective at inhibiting the enZyme
topoisomerase I. These amounts are generally from about
45

The tumor targeted approach involving liposomal deliv
ery of core loaded compound/agent addresses multiple clini
cal issues. For example, reduced systemic toxicity can be
achieved. Enhanced exposure at the tumor site in terms of
relative amounts of drug reaching the tumor can also be
achieved. Furthermore, enhanced exposure at the tumor site
can be achieved in terms of prolonging the exposure of drug
there.

The present invention also provides a method of treating
a patient, Which comprises administering a pharmaceutically

50

1*80 mg/kh of body Weight per Week, preferably about 2*40
mg/kg per Week.
The compounds of the present invention may be admin
istered as a pharmaceutical composition containing the
compounds and a pharmaceutically acceptable carrier or
diluent. The compounds can be administered as their ring
open salt forms, since relactoniZation to their active forms
can occur in the body (especially at sites of reduced pH). The
active material can also be mixed With other active materials

55

Which do not impair the desired action and/or supplement
the desired action. The compounds/active materials accord
ing to the present invention can be administered by any

route, for example, orally, nasally, parenterally, intrave
nously, intradermally, subcutaneously, or topically, in liquid

effective amount of a compound of the present invention.
The compound may, for example, be administered to a
patient a?licted With cancer and/or leukemia. The com
pounds of the present invention may also act as antiviral (for

example, anti-HIV) agents and antiparasitic agents. The

liposomes can be actively and/or passively targeted to the
tumor, the liposome encapsulated compound/agent can be
effectively concentrated at the tumor site, therby reducing
exposure of the healthy host tissues to the cytotoxic agent
yet enhancing exposure at the tumor target.
ery of core loaded compound/agent addresses multiple clini
cal issues. For example, reduced systemic toxicity can be

charge impedes retro-diffusion across the liposome bilayer.
The protonated amine also prevents the occurrence of
nucleophilic attack of the amine on the lactone carbonyl. As

charge impedes retro-di?‘usion across the liposome bilayer.
The protonated amine also prevents the occurrence of
nucleophilic attack of the amine on the lactone carbonyl. As

using pH gradients.
containing agent is loaded into the particle. For example, a
gradient created by ammonia gas diffusing out of the lipo

some particle can result in diffusion or active loading of the
compound/agent of the present invention inWard to the core
of the particle. The chemical gradient across the membrane
creates a driving force for the compound/ agent to replace the

or solid form.

For the purposes of parenteral therapeutic administration,
60

pharmaceutically effective amount or dosage is preferably
betWeen 0.01 to 80 mg of one of the compounds of structures

the active ingredient may be incorporated into a solution or
suspension. The solutions or suspensions may also include
the folloWing components: a sterile diluent such as Water:

for injection, suspensions of liposomal particles Whereby the

A, B and/or C per kg of body Weight. More preferably, the
pharmaceutically effective amount or dosage is preferably

kg of body Weight. In general, a pharmaceutically effective

particles contain stable, active drug Within the core of the
particle in a pH controlled and protected environment or
associated to the outside of the particle or any of the bilayers

amount or dosage contains an amount of one of the com

of the particle, saline solution, ?xed oils, polyethylene

betWeen 0.1 to 40 mg of one or more of the compounds per

65
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glycols, glycerine, propylene glycol or other synthetic sol
vents; antibacterial agents such as benZyl alcohol or methyl

-c0minued

parabens; antioxidants such as ascorbic acid or sodium

bisul?te; chelating agents such as ethylenediaminetetraace
tic acid; bulfers such as acetates, citrates or phosphates and 5

agents for the adjustment of tonicity such as sodium chloride
or dextrose. The parenteral preparation can be enclosed in
ampoules, disposable syringes or multiple dose vials made

of glass or plastic.

0

10

HokvgNHBoc

Another mode of administration of the compounds of this

n : 1,2,3

invention is oral. Oral compositions Will generally include

—>

EDCl, DMAP, cnzcl2

an inert diluent or an edible carrier. They may be enclosed

in gelatin capsules or compressed into tablet. For the pur
pose of oral therapeutic administration, the aforesaid com- 15

pounds may be incorporated With excipients and used in the

form of tablets, troches, capsules, elixirs, suspensions, syr
ups, Wafers, cheWing gums and the like.
The tablets, pills, capsules and the like may contain the
folloWing ingredients: a binder such as microcrystalline

20

cellulose, gum tragacanth or gelatin; an excipient such as
starch or lactose, a disintegrating agent such as alginic acid,
Primogel, corn starch and the like; a lubricant such as
magnesium stearate or Sterotes; a glidant such a colloidal
silicon dioxide; and a sWeetening agent such as sucrose or

25

saccharin or ?avoring agent such as peppermint, methyl
salicylate, or orange ?avoring may be added. When the
dosage unit is in the form of a capsule, it may contain, in
addition to material of the above type, a liquid carrier such
as a fatty oil. Other dosage unit forms may contain other

various materials Which modify the physical form of the
dosage unit, for example, as coatings. Thus tablets or pills
may be coated With sugar, shellac, or other enteric coating
agents. A syrup may contain, in addition to the active
compounds, sucrose as a sWeetening agent and certain

35

preservatives, dyes and coloring and ?avors. Materials used
in preparing these various compositions should be pharma
ceutically or veterinarally pure and non-toxic in the amount
used.

u
40

The folloWing examples are presented to further illustrate
the invention, but it is not to be considered as limited thereto.
EXAMPLE 1
45

Preparation of DB-67 20(S) uu-aminoalkanoanic
esters

DB-67 uu-aminoalkanoanic esters Were synthesiZed as

folloWing:

50

55

MOMCl, DIPEA

o

NHBOC
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DB-67 (1 equiv) Was dissolved in anhydrous dichlo
romethane, and DIPEA (5 equiv) Was added under nitrogen

-continued

atmosphere. The reaction mixture Was stirred for 10 min at

room temperature followed by the addition of MOMCI (5

equiv). The resulting solution Was left stirring overnight.
The reaction Was terminated. Then the reaction mixture Was

diluted by dichloromethane and Washed several times With

Water, dried (MgSO4), ?ltered, and concentrated. Puri?ca
tion by chromatography on silica gel gave 10-MOM pro

tected compound.

1-Ethyl-3 -(3 -dimethylaminopropyl)carbodiimide (EDCI,
3 equiv) Was sloWly added to a solution of 10-MOM

protected compound (1 equiv), N-tert-butoxycarbonylamino
acid (3 equiv) and 4-(Dimethylamino)pyridine (DMAP, 0.6
equiv) and anhydrous dichloromethane, Which had been
pre-cooled to 00 C. The resulting solution Was alloWed to
Warm to room temperature and stirred overnight. The

/0

organic fraction Was Washed With HCl (0.1 N) and Water and

then extracted several times With CH2Cl2. Organic layers
Were combined and dried With MgSO4, folloWed by ?ltra
tion and concentration. Puri?cation of this residue by ?ash

by stirring MOM and N-BOC protected prodrug in dichlo

,CH3

“CF3COOH

O
20

A solution of 7-t-butyldimethylsilyl-10-MOM-hydroxy

chromatography on silica gel gave chloromethyl methyl
ether (MOM) and N-BOC protected prodrug. Deprotection
of MOM and N-BOC groups Was achieved simultaneously

YE

20(s)-CPT (100 mg, 0.19 mmol), N-(tert-butoxycarbonyl)
25

metylyglycine (90 mg, 0.48 mmol) and DMAP (14 mg, 0.12

romethane and tri?uoracetic acid for 30 minutes at room

mmol) in 10 ml anhydrous dichloromethane Was cooled to

temperature, folloWed by concentration under high vacuum
and recrystaliZation in methanol and ethyl ether. Purity of
?nal products Was determined by HPLC and prodrug purity

00 C., folloWed by the addition of EDCI (110 mg, 0.57

Was found to be greater than 98% pure.

mmol). The reaction mixture Was alloWed to come to room
30

EXAMPLE 2

Synthesis of DB-67 20-O-ester of N-methylglycine,

35

mono (tri?uoroacetate)

temperature and monitored by TLC. The resulting solution
Was Washed With HCl (5 ml, 0.1 N) and Water, then extracted
With dichloromethane. The organic layer Was dried With
MgSO4, then ?ltered and concentrated. Puri?cation by col

umn chromatography on silica gel (CH2Cl2iCH3COCH3,

40

45

95:5) gave yelloW solid (120 mg, 90%). lHNMR (400 MHZ,
CDCl3): 0.70 (s, 6H), 1.01 (m, 12H), 1.45 (d, 1:48, 9H),
2.1(%2.34 (m, 2H), 2.96 (s, 3H), 3.54 (s, 3H), 4.05431 (AB
system, 2H), 5.27 (m, 2H), 5.32 (s, 2H), 5375.42 (A ofAB
system, 1H), 56845.72 (B ofAB system, 1H), 7.13, 7.30 (ss,
1H), 74647.51 (m, 1H), 79147.94 (dd, 1:64, 1:24, 1H),
8.054816 (dd, 1:328, 1:92, 1H). 7-t-butyldimethylsilyl
10-MOM-hydroxy-20(s)-CPT-20-O-ester of N-tert-butoxy
carbonylmethyglycine (100 mg, 0.14 mmol) Were dissolved
in dichloromethane and tri?uoracetic acid, then stirred 30

50

min. at room temperature. The yelloW solution Was concen

trated under high vacuum. RecrystaliZation by methanol and
ethyl ether obtained yelloW solid 86 mg, yield 90%. lHNMR
55

(400 MHZ, CD30D): 0.73 (s, 6H), 1.02 (s, 9H), 1.08 (t,
J:7.2, 1H), 42744.40 (q, 1:168, 2H), 5.35 (s, 2H),
5475.51 (A of AB system, 1H), 5.634567 (B of AB

system, 1H), 7.34 (s, 1H), 74247.45 (dd, 1:92, 1:12, 1H),
7.67 (d, 1:28, 1H), 8.19 (d, 1:92, 1H).

US 7,064,206 B1
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EXAMPLE 3

Conversion of DB-67 20(S) uu-aminoalkanoanic
esters to lactam, ortho lactone and acetic acid

prodrugs

Glycinate Ester of DB-67: R1 : Si(CH3)2C(CH3)3, R3 I OH

At physiological pH of 7 or above, the nucleophilicity of
the amine group of DB-67 20(S)-glycinate ester manifests
itself and cycliZation to the C-21 carbonyl carbon occurs.

This cycliZation triggers a rapid and convenient non-enZy
matic decomposition process that releases active DB-67.
DB-67 20(S)-glycinate 1 decomposed to produce several
products: the closed-ring lactone form of DB-67 5, the
ring-opened carboxylate form of DB-67 6, and tWo novel

decomposition products 3 and 4 generated folloWing the
formation of an unusual six membered morpholine 2,5

dione ring 2 (or lactam intermediate). The lactam interme
diate arose by intramolecular nucleophilic attack of the
amino group on the lactone E-ring carbonyl carbon of
DB-67 and is in fast equilibrium With structures 3 (Which We
refer to as the ortho lactone) and 4. Ortho lactone 3 arose by
a second intramolecular reaction Within the lactam interme
diate and 3 exhibited the same mass as DB-6 20(S)-glycinate

ester but With a strikingly different fragmentation pattern. 4

EXAMPLE 4

Procedure for the isolation of the ortho lactone

from N-methyl DB-67 glycinate ester
N-methyl DB-67 glycinate tri?uoroacetic acid salt Was
dissolved in DMF, 1.2 eq. triethylamine Was then added and
reaction stirred overnight at room temperature. Organic
solvent Was removed and a yelloW precipitate Was rinsed
With Water, ?ltered, and dried under vacuum. Yield: 98%.

EXAMPLE 5

Loading of Compounds of Present Invention into

Liposomes
Remote “active” loading of prodrug into premade small
unilamellar vesicles, With diameters of 100 nm, Was carried

out by using transmembrane ammonium sulfate gradients.

arose by a competitive intermolecular reaction to the lactam
intermediate and reacted to release both 5 and 6. ESl/MS/

Prodrug Was added to a liposomal suspension Where initially

MS shoWed that DB-67 glycinate ester fragmentation pat
tern [m/Z(%)] Was: 536 (100%), 461 (50%), 433 (20%);

prodrug occurred as a result of base exchange (initiated by

DB-67 ortho lactone fragmentation pattern Was: 536

(100%), 518 (10%).

[(NH4)2SO4]CORE' [(NH4)2SO4]EXTERNAL; loading of the
NH3 gas molecules departing the liposome). Whereas
underivatiZed camptothecin and DB-67 localiZe predomi
nantly in the bilayer compartment of the liposome, their

US 7,064,206 B1
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20-OR prodrugs, Where R) CO[CH2]nNH 2 and n) 1*3,

C2_l5 alkenyl group, a C2_ 15 alkynyl group, a phenyl group,
a napthyl group, a (CH2)YRl8 group, a (CH2)YC(O)Rl8

loaded With high ef?ciency (60 to 90%) into the core of

liposomes at clinically relevant drug-to-lipid ratios (between

group or a (CH2)YCO2Rl8 Wherein Y may be an integer
ranging from 1 to 15 and R18 is a hydroxy group, a thiol
group, an alkylthiol, a silyl group, an alkoxy group, an
amino group, an alkylamino group, a dialkylamino group, a
halogen atom, a cyano group, a nitro group.

1:4 to 1:20). More importantly, these core-loaded liposomal
formulations of camptothecin 4-aminobutanoate ester and
DB-67 4-aminobutanoate ester exhibited markedly
improved stabilities in Whole blood relative to their free
forms. Whereas the decomposition of free prodrug in both
cases Was extensive, liposomal entrapment prevented the

2. A compound having the formula:

degradation process from occurring, providing indirect evi
dence that the prodrug Was effectively retained Within the
liposome for periods up to 40 h. These time periods are
knoWn to be sufficient for successful tumor-targeting to be
achieved.
What is claimed is:

R1

1. A compound having the formula:
OH

R1
20

25

wherein R1 and R2 are independently the same or different
and are hydrogen, an alkyl group, an alkenyl group, an
alkynyl group, an alkoxy group, a phenoxy group, a napthy

loXy group, an acyloxy group, OC(O)ORl2 wherein R12 is an
alkyl group, a carbamoyloxy group, a halogen, a hydroxy

OH

group, a nitro group, a cyano group, an aZido group, a formyl

group, a hydraZino group, C(O)Rl3 wherein R13 is an alkyl
30

group, an alkoxy group, an amino group or a hydroxy group,

SRM, wherein R14 is hydrogen, C(O)Rl3, an alkyl group, or

wherein R1 and R2 are independently the same or different
and are hydrogen, an alkyl group, an alkenyl group, an
alkynyl group, an alkoxy group, a phenoxy group, a napthy

a phenyl group, a napthyl group; R3 is H, a nitro group, a
halogen atom, an amino group, a hydroxy group, or a cyano

group, a nitro group, a cyano group, an aZido group, a formyl

group; R4 is H, F, an alkyl group, an alkenyl group, an
alkynyl group, a trialkylsilyl group or an alkoxy group; R5
is a Cl_l5 alkyl group, an allyl group, a benZyl group or a

group, a hydraZino group, C(O)Rl3 wherein R13 is an alkyl

propargyl group; R6, R7 and R8 are independently a C1_l5

group, an alkoxy group, an amino group or a hydroxy group,

alkyl group, a C2_ 15 alkenyl group, a C2_l5 alkynyl group, a
phenyl group, a napthyl group or a (CH2)qRl5 group,
Wherein q is an integer betWeen 1 and 15 and R15 is a
hydroxy group, alkoxy group, an amino group, an alky

loXy group, an acyloxy group, OC(O)ORl2 wherein R12 is an
alkyl group, a carbamoyloxy group, a halogen, a hydroxy

35

SR14, wherein R14 is hydrogen, C(O)Rl3, an alkyl group, a
phenyl group or a napthyl group; R3 is H, a nitro group, a
halogen atom, an amino group, a hydroxy group, or a cyano

40

group; R4 is H, F, an alkyl group, an alkenyl group, an
alkynyl group, a trialkylsilyl group or an alkoxy group; R5
is a Cl_l5 alkyl group, an allyl group, a benZyl group or a

propargyl group; R6, R7 and R8 are independently a Cl_l5
alkyl group, a C2_ 15 alkenyl group, a C2_l5 alkynyl group, a
phenyl group, a napthyl group or a (CH2)qRl5 group,
Wherein q is an integer betWeen 1 and 15 and R15 is a
hydroxy group, alkoxy group, an amino group, an alky
lamino group, a dialkylamino group, a halogen atom, a

45

R11 is hydrogen, an alkyl group, an alkenyl group and
(CHZ)LNRI6Rl7 Wherein L may be an integer ranging from
1*30 and R16 and R17 are independently the same or differ
50

same or different and are hydrogen, a Cl_l5 alkyl group, a

ent and are hydrogen, a Cl_l5 alkyl group, a C2_l5 alkenyl
group, a C2_l5 alkynyl group, a phenyl group, a napthyl
group, a (CH2)YRl8 group, a (CH2)YC(O)Rl8 group or a

cyano group or a nitro group; R9 is a hydrogen, an alkyl
group, an alkenyl group, an alkynyl group, an alkoxy group,
a phenoxy group, a napthyloxy group, or an acyloxy group;
R10 is an alkylene group, an alkenylene group or an alky

nylene group; R11 is hydrogen, an alkyl group, an alkenyl
group and (CH2)LNRl6Rl7 Wherein L may be an integer
ranging from 1*30 and R16 and R17 are independently the

lamino group, a dialkylamino group, a halogen atom, a
cyano group or a nitro group; R9 is a hydrogen, an alkyl
group, an alkenyl group, an alkynyl group, an alkoxy group,
a phenoxy group, a napthyloxy group, or an acyloxy group;

(CH) YCO2R18 Wherein Y may be an integer ranging from 1

55

to 15 and R1 8 is a hydroxy group, a thiol group, an alkylthiol,
a silyl group, an alkoxy group, an amino group, an alky
lamino group, a dialkylamino group, a halogen atom, a
cyano group, a nitro group.
*
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